Merck Millipore has confirmed the shutdown of the chromatography company SeQuant in Umeå, Sweden.
Resources and functions based in Umeå will be transferred to Darmstadt Germany and Millipore AB in Sweden. The transmission will enable Merck Millipore to continue to develop its analytical chromatography portfolio using SeQuants technology resources.
The pharma company has lately announced several encouraging results from its ongoing clinical trials in lung cancer, gastric cancer, colorectal cancer and liver cancer. The Phase III ADAURA trial showed for example that treatment with Tagrisso after surgery with curative intent reduced the risk of disease recurrence or death by…
Recipharm has announced an investment of over €1.2 million to enhance its small scale GMP active pharmaceutical ingredient (API) development and manufacturing capabilities in Paderno Dugnano, Italy. The investment, which is in response to growing demand for Recipharm’s custom synthesis and early phase API manufacturing capabilities, has seen the opening…
The Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing anthrax vaccine development contract with Altimmune by awarding an additional $3.7 million. The increase in funding is primarily directed toward a Phase 1b clinical trial of NasoShield to evaluate alternative methods of intranasal dosing in humans. Phae Ib…
The company has received a positive outcome from the NAD (National Advertising Division) regarding a challenge filed on Fungi-Nail, the largest US competitor to the Kerasal Nail product. NAD recommends the advertiser to discontinue current product packaging and commercials. Moberg Pharma expects the outcome to further strengthen Kerasal Nails position…
